Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Chan Joo | - |
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Ihm, Sang Hyun | - |
dc.contributor.author | Sohn, Il Suk | - |
dc.contributor.author | Woo, Jong Shin | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Choi, Jung Hyun | - |
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Seo, Jae-Bin | - |
dc.contributor.author | Doh, Joon-Hyung | - |
dc.contributor.author | Son, Jung-Woo | - |
dc.contributor.author | Park, Jae-Hyeong | - |
dc.contributor.author | Lee, Ju-Hee | - |
dc.contributor.author | Hong, Young Joon | - |
dc.contributor.author | Heo, Jung Ho | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Kang, Seok-Min | - |
dc.date.accessioned | 2024-03-15T12:00:25Z | - |
dc.date.available | 2024-03-15T12:00:25Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.issn | 1751-7176 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90702 | - |
dc.description.abstract | This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol-lowering effects and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe versus rosuvastatin and ezetimibe double therapy or telmisartan single therapy in dyslipidemia patients with hypertension. After a wash-out/therapeutic lifestyle change period of >= 4 weeks, a total of 100 eligible patients were randomized and received one of three treatments for 8 weeks: (1) telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE), (2) rosuvastatin 20 mg/ezetimibe 10 mg (RE), or (3) telmisartan 80 mg (T). The primary endpoint was the efficacy evaluation of TRE by comparing changes in mean sitting systolic blood pressure (msSBP) and mean percentage change in low-density lipoprotein-C (LDL-C) from baseline after 8 weeks of treatment. The least square (LS) mean (SE) changes in msSBP at 8 weeks compared with baseline were -23.02 (3.04) versus -7.18 (3.09) mmHg in the TRE and RE groups, respectively (p < .0001), and -25.80 (2.74) versus -14.92 (2.65) mmHg in the TRE and T groups, respectively (p = .0005). The percentage changes in the mean (SD) LDL-C at 8 weeks compared with baseline were -54.97% (3.49%) versus -0.17% (3.23%) in the TRE and T groups, respectively (p < .0001). No serious adverse events occurred, and no statistically significant differences in the incidence of overall AEs and adverse drug reactions occurred among the three groups. TRE therapy significantly decreased msSBP and LDL-C compared to RE or T therapy with comparable safety and tolerability profiles. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial | - |
dc.type | Article | - |
dc.identifier.wosid | 001158253200001 | - |
dc.identifier.doi | 10.1111/jch.14778 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.26, no.3, pp 262 - 273 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85184456790 | - |
dc.citation.endPage | 273 | - |
dc.citation.startPage | 262 | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 26 | - |
dc.citation.number | 3 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | combination therapy | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | ezetimibe | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | rosuvastatin | - |
dc.subject.keywordAuthor | telmisartan | - |
dc.subject.keywordPlus | FIXED-DOSE COMBINATION | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | HYPERCHOLESTEROLEMIA | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | METABOLISM | - |
dc.subject.keywordPlus | FACTORIAL | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.